The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Upcoming results from clinical trials for treating relapsed, low grade lymphoma
Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks about the clinical trials with results being released soon for the treatment of low grade lymphoma. Trials include several drugs being combined with lenalidomide, as well as checkpoint inhibitors. Speaking at the 2017 American Society of Hematology (ASH) Annual Meeting, in Atlanta, GA, Dr Fowler describes the potential of CAR T-cell therapy with checkpoint inhibitors, with front-line studies being presented in upcoming meetings.
